Inventiva S.A. Sponsored ADR

IVA Healthcare Biotechnology

Inventiva S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, down 43.7% from fiscal 2024.

2.94 0.17 −5.47%
Market cap
$740.0M
P/E
0.0×
Fwd P/E
−4.6×
Dividend yield
—
F-score
4/9
Altman Z
−1.36
Beneish M
−7.91
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — 3 3 2 2 1 4
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— — — — 9.33 7.20 0.16 (5.68) (4.53) (1.36)
P/S ratio
0.00 44.07 44.07 44.07 70.80 70.85 9.67 9.26 4.22 9.16
Altman Z″-Score (non-manufacturers)
2.10 — — 1.52 7.61 3.61 0.12 (15.61) (11.56) (4.14)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — — — (2.73) (2.33) (3.50) (1.09) (7.35) (7.91)
P/Operating CF
(49.78) (49.78) (49.78) (49.78) (19.22) (36.52) (13.29) (12.57) (1.59) (2.95)
P/B ratio
8.56 8.56 8.56 8.56 4.09 5.28 4.00 0.00 0.00 0.00
Price to Tangible BV
8.78 8.78 8.78 8.78 4.12 5.32 4.05 0.00 0.00 0.00
EV/Sales
38.86 38.86 38.86 38.86 55.75 59.20 6.88 9.48 6.54 5.41
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(5.44) (5.44) (5.44) (5.44) (6.02) (5.23) (1.46) (1.45) (1.23) (0.78)
EV/FCF
(5.44) (5.44) (5.44) (5.44) (6.02) (5.23) (1.46) (1.45) (1.22) (0.77)
Quick Ratio
4.56 7.31 4.64 3.29 8.25 4.15 3.02 0.72 0.85 1.34
Current Ratio
4.80 7.46 4.75 3.53 9.56 5.06 3.47 0.96 0.92 3.16
Net Debt/EBITDA
1.57 2.24 1.67 1.24 3.44 1.43 0.94 (0.11) 0.46 0.29
Debt/Assets
1.28% 0.00% 0.28% 0.20% 7.24% 8.30% 29.75% 53.89% 45.67% 23.99%
Debt/Equity
0.02 0.01 0.00 0.00 0.09 0.11 0.76 (1.17) (0.51) (2.10)
Asset Turnover
0.14 0.22 0.05 0.16 0.05 0.07 0.15 0.25 0.16 0.04
Operating CF/Net income
2.11 0.89 1.02 0.94 0.91 0.96 0.83 0.74 0.47 0.30
Capex/Depreciation
0.00 0.00 0.00 (0.08) (0.15) 0.35 (0.31) (0.16) (0.06) (0.08)
Interest Coverage
(142.66) 0.00 (212.95) (374.30) (4.99) (19.78) (27.11) (14.92) (1.10) (0.65)
ROE
(13.22%) (40.99%) (53.16%) (57.77%) (44.29%) (50.59%) (74.72%) (1,804.49%) 265.66% 542.65%
ROA
(10.52%) (89.41%) (53.98%) (43.52%) (34.52%) (38.76%) (42.91%) (121.02%) (195.41%) (194.96%)
ROIC
0.00% 0.00% 0.00% (334.31%) (119.22%) (262.00%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(18.73%) (30.42%) (55.28%) (78.02%) (27.47%) (51.75%) (65.34%) (1,543.11%) 4,370.44% (208.23%)
Average Days of Receivables
553.41 521.97 1,523.93 318.00 629.44 359.51 116.54 144.33 135.64 197.88
Research and Development Expense of Revenue
221.33% 536.25% 965.53% 299.27% 450.64% 569.96% 321.40% 474.95% 617.18% 1,098.19%
Selling, General and Administrative Expense of Revenue
42.43% 108.15% 190.52% 56.12% 172.18% 135.50% 82.36% 68.29% 120.83% 666.89%
Intangible Assets out of Total Assets
0.04 0.00 0.02 0.02 0.01 0.01 0.00 0.01 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 12.46% 17.82% 24.57% 11.79% 17.13% 24.31% 337.74%
Graham Net Nets
0.09 0.09 0.09 0.09 0.23 0.18 0.20 (0.16) (1.17) (0.09)
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(316.20%) (17.17%) (17.17%) (17.17%) (12.60%) (15.17%) (52.09%) (75.81%) (166.50%) (76.62%)
Free Cash Flow Yield
0.00% (16.21%) (16.21%) (16.21%) (13.09%) (15.97%) (48.84%) (70.80%) (127.43%) (76.47%)
Revenue per Share
0.63 0.37 0.14 0.54 0.18 0.26 0.48 0.55 0.27 0.05
Operating CF per Share
(1.00) (1.32) (1.54) (1.35) (1.03) (1.44) (1.14) (1.95) (1.56) (0.64)
Capex per Share
0.00 0.00 0.00 (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) 0.00
Free Cash Flow per Share
(1.00) (1.32) (1.54) (1.36) (1.04) (1.45) (1.16) (1.96) (1.56) (0.64)
Cash per Share
1.67 4.59 2.56 1.71 3.56 2.61 2.20 0.64 1.75 0.60
Shareholders Equity per Share
2.40 4.81 2.78 1.97 3.75 2.68 1.16 (0.76) (1.93) (0.17)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
2.40 4.81 2.78 1.97 3.75 2.68 1.16 (0.76) (1.93) (0.17)
Free Cash Flow
(15.64) (20.48) (39.32) (31.96) (35.28) (56.88) (47.88) (88.77) (93.34) (118.95)
Working Capital
34.37 70.13 65.00 39.21 136.04 109.70 79.74 (2.13) (9.98) 189.05
Capital Expenditures
(0.24) (0.52) (0.63) (0.15) (0.33) (0.53) (0.55) (0.44) (0.36) (0.28)
Net Current Asset Value
29.59 65.96 61.40 37.30 120.27 97.56 37.78 (57.80) (123.47) (37.97)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.01 0.06 0.05 0.03 0.02 0.02 0.03
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.33 0.31 0.54 0.42 0.58 (0.40) 0.23 0.28 1.04 1.08
Cash ROIC
(24.27%) (14.00%) (28.86%) (36.89%) (13.61%) (25.91%) (27.26%) (253.35%) (194.96%) (80.47%)
Accounts Receivable Turnover
0.85 0.50 0.31 0.96 0.56 0.99 2.44 3.09 2.01 1.66
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — —
Average Receivables
11.67 11.67 11.80 13.18 10.69 10.14 8.12 8.12 7.92 5.39
Average Payables
5.54 5.54 8.05 9.01 8.15 12.59 18.84 30.59 38.17 32.50
Average Inventory
0.53 0.53 0.52 0.45 0.40 0.41 0.43 0.42 — —
Average Assets
70.52 25.72 71.58 77.77 111.24 151.50 133.27 98.75 102.01 205.52
Average Common Equity
56.09 56.09 72.69 58.58 86.70 116.09 76.53 6.62 (75.03) (73.84)

Fold the line items

Columns are period end dates · fundamentals updated 30 Sep 2026